Moody's has performed a regular credit update on Brks.
Everything looks very good :
moodys.com
Fiscal YTD earnings are due out on 11/06 ah.
Brooks Automation, Inc. (Nasdaq: BRKS) will announce fiscal 2019 fourth quarter and year-end earnings which ended September 30, 2019, on Wednesday, November 6, 2019 after the market closes.
Looks to me like fab orders were good for AMAT and LRCX - I'm expecting the same for Brks and genome and storage should have good organic growth.
I admire the C.E.O Steve Schwartz for terminating Dusty, and taking the growth issue on himself.
BROOKS AUTOMATION ANNOUNCES TRANSITION OF SAMPLE MANAGEMENT LEADERSHIP
CHELMSFORD, Mass., Sept. 6, 2019 / PRNewswire/ -- Brooks Automation, Inc. (Nasdaq: BRKS) announced today that Dusty Tenney, President Sample Management, will be leaving Brooks effective September 6, 2019.
"We are deeply appreciative of the contributions Dusty has made to the Sample Management business since joining Brooks in 2014," said Steve Schwartz, President and CEO. "Dusty has led a four-fold increase in Life Science revenue, taken the Sample Management business to profitability, and established a new threshold for Sample Management which we plan to aggressively build going forward. Our employees, the entire management team and board of directors all thank Dusty for his leadership and guidance."
Schwartz continued, "With what has been accomplished, we are now focused on transitioning this business to the next phase of operational execution and commercial growth capability to address the multiple opportunities in the growing sample management markets."
During this transition phase of the Sample Management expansion, Steve Schwartz will assume responsibilities as the leader of the business unit.
About Brooks Automation
Brooks is a leading provider of life science and semiconductor manufacturing automation solutions worldwide. The Company applies its automation and cryogenics expertise to provide a full suite of reliable cold-chain sample management solutions across life sciences in areas such as drug development, clinical research and advanced cell therapies. Brooks recently added global capability for gene sequencing and gene synthesis services through its strategic acquisition of GENEWIZ, expanding its sample-based services offerings. With over 40 years as a partner to the semiconductor manufacturing industry, Brooks is a provider of industry-leading precision robotics, integrated automation systems and services. Brooks is headquartered in Chelmsford, MA, with operations in North America, Europe and Asia. For more information, visit www.brooks.com.
Dr Schwartz is a dynamic leader.
His leadership is worthy of great respect!
Bob |
